Scholars@Duke
Katherine Barnett Peters

Katherine Barnett Peters

Professor of Neurosurgery
Neurosurgery, Neuro-Oncology
katherine.peters@duke.edu
047 Baker House, Trent Drive, BOX_3624, Durham, NC 27710
Office hours Per Request  

Selected Publications

New and Emerging Therapies for Patients with Low-Grade Glioma.

Journal Article CNS Drugs · January 2026 Both pediatric and adult patients can develop low-grade glioma (World Health Organization [WHO] grade 2), a type of primary brain tumor that can impact neurologic function and limit one's ability to thrive and survive. Traditionally, the treatment of low-g ... Full text Link to item Cite

Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial.

Journal Article Lancet Oncol · December 2025 BACKGROUND: In a phase 3 trial, vorasidenib, an oral brain-penetrant inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2), resulted in improved progression-free survival (primary endpoint) and time to next intervention (key secondary endpoint) at ... Full text Link to item Cite

Neurocognitive outcomes in patients with brain metastases: a systematic review.

Journal Article Lancet Oncol · December 2025 Multimodality therapy, including surgery, radiotherapy, and systemic therapy, has significantly improved overall survival for patients with brain metastases. However, treatment-related neurocognitive sequelae remain a major challenge in survivorship. Altho ... Full text Link to item Cite

Clinical trial of feasibility for mindfulness intervention for patients with newly diagnosed high grade glioma.

Journal Article J Neurooncol · November 5, 2025 PURPOSE: With a bleak prognosis for malignant glioma, maintaining quality of life (QoL) and decreasing distress are essential in patient clinical care. Mindfulness meditation is a mind-body therapy that is being investigated as a non-pharmacological strate ... Full text Link to item Cite

Comparing Knowledge and Perceptions of Palliative Care Among Neuro-Oncology Patients, Caregivers, and Providers to a Representative U.S. Sample

Conference American Journal of Hospice and Palliative Medicine · September 1, 2025 Background: Primary brain tumors (PBTs) pose a significant health challenge, affecting patients and their caregivers. While early integration of palliative care (PC) has shown benefits in advanced cancer, its integration for PBT patients, particularly glio ... Full text Cite

A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial.

Journal Article Nat Cancer · September 2025 The human cytomegalovirus (CMV) antigen pp65 is expressed in high-grade glioma (HGG) and medulloblastoma but not in the adjacent brain. This single-arm phase 1 trial ( NCT03299309 ) assessed the safety and immunogenicity of a peptide vaccine (PEP-CMV) targ ... Full text Link to item Cite

Frequency, Risk Factors, and Outcomes of Strokes in Patients With Primary Glioma After Cranial Radiation Therapy.

Journal Article Neurology · August 12, 2025 BACKGROUND AND OBJECTIVES: Radiation therapy is the mainstay of therapy for patients with glioma. While this treatment modality can improve survival, treatment-related complications may include radiation-induced vasculopathy and increased risk of stroke. W ... Full text Link to item Cite

Phase II randomized glioma study to evaluate efficacy and satisfaction of rolapitant plus ondansetron in preventing chemoradiation-induced nausea and vomiting.

Journal Article Neurooncol Pract · August 2025 BACKGROUND: Nausea and vomiting remain feared cancer treatment-related side effects. Antiemetic guideline trials exclude malignant glioma patients. In patients receiving radiation with concurrent temozolomide, chemoradiation-induced nausea; vomiting (cRINV ... Full text Link to item Cite

The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.

Journal Article Neuro Oncol · June 21, 2025 Isocitrate dehydrogenase (IDH)-mutant gliomas are the most common malignant primary brain tumors in young adults. This condition imposes a substantial burden on patients and their caregivers, marked by neurocognitive deficits and high mortality rates due t ... Full text Link to item Cite

Seizure risk factors and management approaches in patients with brain metastases.

Journal Article Neurooncol Pract · June 2025 A significant proportion of patients with brain metastases experience a seizure event during their disease course, which can impact morbidity and long-term outcomes. A host of factors elevate the risk for seizures in patients with brain metastases, includi ... Full text Link to item Cite

Molecular Testing for the World Health Organization Classification of Central Nervous System Tumors: A Review.

Journal Article JAMA Oncol · March 1, 2025 IMPORTANCE: Molecular techniques, including next-generation sequencing, genomic copy number profiling, fusion transcript detection, and genomic DNA methylation arrays, are now indispensable tools for the workup of central nervous system (CNS) tumors. Yet t ... Full text Link to item Cite

Financial toxicity of oral chemotherapy in patients with primary brain tumors.

Journal Article Neurooncol Pract · February 2025 BACKGROUND: Cancer treatment costs continue to rise with the development of new agents. Financial toxicity is defined as the quantifiable costs associated with cancer and cancer treatment in addition to the patient's associated distress. This study's ratio ... Full text Link to item Cite

Symptom management in isocitrate dehydrogenase mutant glioma.

Journal Article Neurooncol Pract · February 2025 According to the 2021 World Health Organization classification of CNS tumors, gliomas harboring a mutation in isocitrate dehydrogenase (mIDH) are considered a distinct disease entity, typically presenting in adult patients before the age of 50 years. Given ... Full text Link to item Cite

The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?

Journal Article Neuro Oncol · October 3, 2024 The 2016 and 2021 World Health Organization 2021 Classification of central nervous system tumors have resulted in a major improvement in the classification of isocitrate dehydrogenase (IDH)-mutant gliomas. With more effective treatments many patients exper ... Full text Link to item Cite

Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients.

Journal Article Cancer · May 1, 2024 Management of venous thromboembolism (VTE) in patients with primary and metastatic brain tumors (BT) is challenging because of the risk of intracranial hemorrhage (ICH). There are no prospective clinical trials evaluating safety and efficacy of direct oral ... Full text Link to item Cite

Comparison of differing dose levels of methotrexate for patients with primary central nervous system lymphoma.

Journal Article J Oncol Pharm Pract · April 2024 INTRODUCTION: It has long been established that high-dose methotrexate is an essential part of therapy for primary central nervous system lymphoma. When regimens utilizing high-dose methotrexate were first studied, a dose of 8 g/m2 was used. More recently, ... Full text Link to item Cite

Use, access, and initial outcomes of off-label ivosidenib in patients with IDH1 mutant glioma.

Journal Article Neurooncol Pract · April 2024 BACKGROUND: Isocitrate dehydrogenase (IDH) is commonly mutated (mIDH) in gliomas, and this mutant enzyme produces the oncometabolite 2-hydroxyglutarate (2HG). 2HG promotes gliomagenesis and is implicated in epileptogenesis. Ivosidenib (IVO), a small molecu ... Full text Link to item Cite

Discontinuation of Antiseizure Medications in Patients With Brain Tumors.

Journal Article Neurology · February 27, 2024 Patients with brain tumors will experience seizures during their disease course. While providers can use antiseizure medications to control these events, patients with brain tumors can experience side effects, ranging from mild to severe, from these medica ... Full text Link to item Cite

A systematic review of the impact of brain tumours on risk of motor vehicle crashes.

Journal Article J Neurooncol · February 2024 PURPOSE: Brain tumours are associated with neurocognitive impairments that are important for safe driving. Driving is vital to maintaining patient autonomy, despite this there is limited research on driving capacity amongst patients with brain tumours. The ... Full text Link to item Cite

Coexisting Biopsy-Diagnosed Dementia and Glioblastoma.

Journal Article Brain Sci · January 30, 2024 Both glioblastoma (GBM) and dementia are devastating diseases with limited treatments that are usually not curative. Having clinically diagnosed dementia with an associated biopsy-proven etiology and a coexisting GBM diagnosis is a rare occurrence. The rel ... Full text Link to item Cite

Outcomes and immune response after peptide vaccination targeting human cytomegalovirus antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma

Conference Journal of Clinical Oncology · January 1, 2024 Background: The human cytomegalovirus (CMV) antigen pp65 is ubiquitously expressed in high-grade glioma (HGG) and medulloblastoma but not in adjacent brain. The primary objective of this first-in-human phase I trial (NCT03299309) was to assess the safety a ... Full text Cite

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.

Journal Article N Engl J Med · August 17, 2023 BACKGROUND: Isocitrate dehydrogenase (IDH)-mutant grade 2 gliomas are malignant brain tumors that cause considerable disability and premature death. Vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes, showed preliminary activity ... Full text Link to item Cite

Use of Trametinib in Children and Young Adults With Progressive Low-grade Glioma and Glioneuronal Tumors.

Journal Article J Pediatr Hematol Oncol · May 1, 2023 Low-grade gliomas/glioneuronal tumors comprise one-third of all pediatric-type CNS tumors. These tumors are generally caused by activating mutations in the mitogen-activated protein kinase (MAPK) pathway. Targeted drugs, such as trametinib, have shown prom ... Full text Link to item Cite

Clinical management of seizures in patients with meningiomas: Efficacy of surgical resection for seizure control and patient-tailored postoperative anti-epileptic drug management.

Journal Article Neurooncol Adv · May 2023 Meningiomas are the most common primary intracranial tumor. They are slow growing and often incidentally found tumors that arise from the arachnoid villi. As they grow, they have a greater likelihood of becoming symptomatic with seizures being one of the m ... Full text Link to item Cite

Novel Mechanisms and Future Opportunities for the Management of Radiation Necrosis in Patients Treated for Brain Metastases in the Era of Immunotherapy.

Journal Article Cancers (Basel) · April 24, 2023 Radiation necrosis, also known as treatment-induced necrosis, has emerged as an important adverse effect following stereotactic radiotherapy (SRS) for brain metastases. The improved survival of patients with brain metastases and increased use of combined s ... Full text Link to item Cite

Determining venous thromboembolism risk in patients with adult-type diffuse glioma.

Journal Article Blood · March 16, 2023 Venous thromboembolism (VTE) is a life-threating condition that is common in patients with adult-type diffuse gliomas, yet thromboprophylaxis is controversial because of possible intracerebral hemorrhage. Effective VTE prediction models exist for other can ... Full text Link to item Cite

Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.

Journal Article Nat Med · March 2023 Vorasidenib and ivosidenib inhibit mutant forms of isocitrate dehydrogenase (mIDH) and have shown preliminary clinical activity against mIDH glioma. We evaluated both agents in a perioperative phase 1 trial to explore the mechanism of action in recurrent l ... Full text Link to item Cite

Caregiver survey in glioblastoma focused on cognitive dysfunction: development and results from a multicenter study.

Journal Article Future Oncol · January 2023 Aim: To develop a cognitive dysfunction (CD) focused questionnaire to evaluate caregiver burden in glioblastoma. Materials & methods: The survey was developed from stakeholder consultations and a pilot study, and disseminated at eight US academic cancer ce ... Full text Link to item Cite

NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022.

Journal Article J Natl Compr Canc Netw · January 2023 The NCCN Guidelines for Central Nervous System (CNS) Cancers focus on management of the following adult CNS cancers: glioma (WHO grade 1, WHO grade 2-3 oligodendroglioma [1p19q codeleted, IDH-mutant], WHO grade 2-4 IDH-mutant astrocytoma, WHO grade 4 gliob ... Full text Link to item Cite

Long-term outcomes with reduced-dose whole-brain radiotherapy and a stereotactic radiosurgery boost for primary central nervous system lymphoma.

Journal Article Neurooncol Adv · 2023 BACKGROUND: Primary central nervous system lymphoma (PCNSL) is an aggressive diffuse large B-cell lymphoma. Treatment approaches are historically associated with neurotoxicity, particularly with high-dose whole-brain radiotherapy (WBRT). We hypothesized th ... Full text Link to item Cite

Physician, patient, and caregiver support for a formal certification in pediatric neuro-oncology: A survey-based report from the SNO pediatrics working group.

Journal Article Neurooncol Adv · 2023 BACKGROUND: Although CNS tumors are the most common pediatric cancer in the United States, most physicians caring for these patients are not formally certified in the subspecialty. To determine support for developing a formal certification process in pedia ... Full text Link to item Cite

Targeting Mutant IDH to Treat Low-grade Glioma

Journal Article European Oncology and Haematology · January 1, 2023 dult-type diffuse low-grade gliomas (LGGs) develop in young adults and represent 5–10% of all primary brain tumours. While patients with LGG can survive longer than those with higher-grade tumours, progression, transformation and, ultimately, mortality occ ... Full text Cite

Geriatric Assessment Reveals Actionable Impairments in Hematopoietic Stem Cell Transplantation Candidates Age 18 to 80 Years.

Journal Article Transplant Cell Ther · August 2022 Allogeneic hematopoietic stem cell transplantation (HCT) is a potentially curative treatment for both malignant and nonmalignant hematologic diseases; however, reported rates of treatment-related mortality approach 30%. Outcomes are worse in patients who b ... Full text Link to item Cite

Rural-Urban Disparities in Cancer Outcomes: Opportunities for Future Research.

Journal Article J Natl Cancer Inst · July 11, 2022 Cancer care disparities among rural populations are increasingly documented and may be worsening, likely because of the impact of rurality on access to state-of-the-art cancer prevention, diagnosis, and treatment services, as well as higher rates of risk f ... Full text Link to item Cite

Cold Plasma Discharge Tube Enhances Antitumoral Efficacy of Temozolomide.

Journal Article ACS Appl Bio Mater · April 18, 2022 Glioblastoma (GBM) is a fatal human brain tumor with a low survival rate. Temozolomide (TMZ) has been widely used in GBM therapy with noticeable side effects. Cold plasma is an ionized gas that is generated near room temperature. Here, we demonstrated the ... Full text Link to item Cite

Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial.

Journal Article Support Care Cancer · April 2022 PURPOSE: At diagnosis and throughout the disease course, patients with high-grade glioma (HGG) experience a diminished quality of life (QOL) and increased fatigue. Naltrexone, an orally semisynthetic opiate antagonist, is FDA-approved for the treatment of ... Full text Link to item Cite

Caregiver burden by treatment and clinical characteristics of patients with glioblastoma.

Journal Article Support Care Cancer · February 2022 BACKGROUND: Glioblastoma is an incurable disease with a poor prognosis. For caregivers of people with glioblastoma, the burden of care can be high. Patients often present with different clinical characteristics, which may impact caregiver burden in differe ... Full text Link to item Cite

Availability and role of clinical pharmacists in ambulatory neuro-oncology.

Journal Article Neurooncol Pract · February 2022 BACKGROUND: Outpatient clinics treating neuro-oncology patients are becoming more multidisciplinary. Utilization of all team members is critical for the holistic care of these complex patients. Specifically, the role of clinical pharmacist (CP) in the ambu ... Full text Link to item Cite

Long-Term Outcomes for Patients With Atypical or Malignant Meningiomas Treated With or Without Radiation Therapy: A 25-Year Retrospective Analysis of a Single-Institution Experience.

Journal Article Adv Radiat Oncol · 2022 PURPOSE: Atypical (World Health Organization [WHO] grade 2) and malignant (WHO grade 3) meningiomas have high rates of local recurrence, and questions remain about the role of adjuvant radiation therapy (RT) for patients with WHO grade 2 disease. These pat ... Full text Link to item Cite

Resolution of radiation necrosis with bevacizumab following radiation therapy for primary CNS lymphoma.

Journal Article Oncotarget · 2022 IMPORTANCE: Radiation necrosis (RN) is a rare but serious adverse effect following treatment with radiation therapy. No standard of care exists for the management of RN, and efforts to prevent and treat RN are limited by a lack of insight into the pathomec ... Full text Link to item Cite

Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline.

Journal Article Pract Radiat Oncol · 2022 PURPOSE: This guideline provides evidence-based recommendations for adults with isocitrate dehydrogenase (IDH)-mutant grade 2 and grade 3 diffuse glioma, as classified in the 2021 World Health Organization (WHO) Classification of Tumours. It includes indic ... Full text Link to item Cite

Multi-joint steroid-induced avascular necrosis in a malignant brain tumor patient.

Journal Article CNS Oncol · December 1, 2021 Avascular necrosis (AVN) is a rare but serious adverse event associated with the use of corticosteroids for long durations or at high doses. This case report describes a 47-year-old female patient with low-grade astrocytoma who was initiated on low-dose de ... Full text Link to item Cite

Palliative Care Use for Critically Ill Patients With Brain Metastases.

Journal Article J Pain Symptom Manage · November 2021 CONTEXT: Critically ill patients with brain metastases (BM) face significant uncertainty regarding prognosis and survival and can benefit from Palliative care (PC). However, research regarding the role of PC in this population is lacking. OBJECTIVES: We so ... Full text Link to item Cite

Preservation of neurocognitive function in the treatment of brain metastases.

Journal Article Neurooncol Adv · November 2021 Neurocognitive function (NCF) deficits are common in patients with brain metastases, occurring in up to 90% of cases. NCF deficits may be caused by tumor-related factors and/or treatment for the metastasis, including surgery, radiation therapy, chemotherap ... Full text Link to item Cite

Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis.

Journal Article CNS Oncol · September 1, 2021 Purpose: To describe our population of primary brain tumor (PBT) patients, a subgroup of cancer patients whose intensive care unit (ICU) outcomes are understudied. Methods: Retrospective analysis of PBT patients admitted to an ICU between 2013 to 2018 for ... Full text Open Access Link to item Cite

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.

Journal Article Clin Cancer Res · August 15, 2021 PURPOSE: Lower grade gliomas (LGGs) are malignant brain tumors. Current therapy is associated with short- and long-term toxicity. Progression to higher tumor grade is associated with contrast enhancement on MRI. The majority of LGGs harbor mutations in the ... Full text Link to item Cite

Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group.

Journal Article Support Care Cancer · June 2021 Cancer-related cognitive impairment (CRCI) is commonly experienced by individuals with non-central nervous system cancers throughout the disease and treatment trajectory. CRCI can have a substantial impact on the functional ability and quality of life of p ... Full text Link to item Cite

Diffuse midline glioma with H3 K27M-mutation in an 83-year-old woman.

Journal Article CNS Oncol · June 1, 2021 Diffuse midline gliomas harboring histone H3 K27M mutations are most commonly found in the brainstem of children. This mutation confers a WHO grade IV designation and is associated with a particularly poor prognosis. Although traditionally considered to be ... Full text Link to item Cite

Spiritual well-being and its association with health-related quality of life in primary brain tumor patients.

Journal Article Neurooncol Pract · June 2021 BACKGROUND: Spirituality can impact patients' attitudes and decisions about treatment and end-of-life care when coping with cancer. Previous studies documented health-related quality of life (HRQoL) and spiritual well-being (SWB) as positively correlated w ... Full text Link to item Cite

When tumefactive demyelination is truly a tumor: case report of a radiographic misdiagnosis.

Journal Article CNS Oncol · March 1, 2021 Oligodendrogliomas are slow-growing tumors that account for 15-20% of gliomas. This case report describes the case of an adult male patient diagnosed initially with tumefactive demyelination and multiple sclerosis, which was subsequently found to be a well ... Full text Link to item Cite

Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.

Journal Article Clin Cancer Res · February 15, 2021 PURPOSE: VEGF is upregulated in glioblastoma and may contribute to immunosuppression. We performed a phase II study of pembrolizumab alone or with bevacizumab in recurrent glioblastoma. PATIENTS AND METHODS: Eighty bevacizumab-naïve patients with recurrent ... Full text Link to item Cite

What is New in Neuro-oncology?

Journal Article Neurol Clin · February 2021 Neuro-oncology is a rapidly developing field. A continuous evolution in the understanding of the molecular underpinnings of central nervous system tumors has helped reconfigure the classification of brain tumors. More importantly, it has laid the path forw ... Full text Link to item Cite

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.

Journal Article Nat Commun · January 13, 2021 Several immunotherapy clinical trials in recurrent glioblastoma have reported long-term survival benefits in 10-20% of patients. Here we perform genomic analysis of tumor tissue from recurrent WHO grade IV glioblastoma patients acquired prior to immunother ... Full text Open Access Link to item Cite

The state of neuro-oncology during the COVID-19 pandemic: A worldwide assessment

Conference Neuro Oncology Advances · January 1, 2021 Background:It remains unknown how the COVID-19 pandemic has changed neuro-oncology clinical practice, training, and research efforts. Methods:We performed an international survey of practitioners, scientists, and trainees from 21 neuro-oncology organizatio ... Full text Cite

Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis.

Journal Article Front Oncol · 2021 OBJECTIVES: Standard 6-week and hypofractionated 3-week courses of adjuvant radiation therapy (RT) are both options for older patients with glioblastoma (GBM), but deciding the optimal regimen can be challenging. This analysis explores clinical factors ass ... Full text Open Access Link to item Cite

The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment.

Journal Article Neurooncol Adv · 2021 BACKGROUND: It remains unknown how the COVID-19 pandemic has changed neuro-oncology clinical practice, training, and research efforts. METHODS: We performed an international survey of practitioners, scientists, and trainees from 21 neuro-oncology organizat ... Full text Link to item Cite

Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment.

Conference Neuro Oncol · December 18, 2020 BACKGROUND: Lower-grade gliomas (LGGs) with isocitrate dehydrogenase 1 and/or 2 (IDH1/2) mutations have long survival times, making evaluation of treatment efficacy difficult. We investigated the volumetric growth rate of IDH mutant gliomas before and afte ... Full text Link to item Cite

Health care resource utilization and treatment of leptomeningeal carcinomatosis in the United States.

Journal Article Neurooncol Pract · December 2020 BACKGROUND: The economic burden of cancer in the United States is substantial, and better understanding it is essential in informing health care policy and innovation. Leptomeningeal carcinomatosis (LC) represents a late complication of primary cancer spre ... Full text Link to item Cite

Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.

Journal Article J Natl Compr Canc Netw · November 2, 2020 The NCCN Guidelines for Central Nervous System (CNS) Cancers focus on management of adult CNS cancers ranging from noninvasive and surgically curable pilocytic astrocytomas to metastatic brain disease. The involvement of an interdisciplinary team, includin ... Full text Link to item Cite

Outcomes Following Adjuvant Radiation Therapy in Elderly Patients with Glioblastoma: A Retrospective Single Institution Analysis

Conference International Journal of Radiation Oncology*Biology*Physics · September 1, 2020 2230 ... Full text Link to item Cite

RAF and MEK inhibitor therapy in adult patients with brain tumors: a case-based overview and practical management of adverse events.

Journal Article Neurooncol Pract · July 2020 Targeted therapy has gained mainstream attention with notable successes against specific genetic mutations in many cancers. One particular mutation, the BRAF V600E mutation, is present in a small subset of gliomas in adults. Although clinical experience an ... Full text Link to item Cite

Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study.

Journal Article Neuro Oncol · May 15, 2020 BACKGROUND: VB-111 is a non-replicating adenovirus carrying a Fas-chimera transgene, leading to targeted apoptosis of tumor vascular endothelium and induction of a tumor-specific immune response. This phase I/II study evaluated the safety, tolerability, an ... Full text Link to item Cite

Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.

Journal Article Support Care Cancer · May 2020 PURPOSE: CINV remains a distressing side effect experienced by glioma patients receiving multi-day temozolomide therapy, in spite of guideline-based antiemetic therapy with selective serotonin-receptor-antagonists. Antiemetic research with aprepitant has r ... Full text Link to item Cite

Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.

Journal Article J Neurooncol · April 2020 PURPOSE: Primary central nervous system lymphoma (PCNSL) is a subtype of non-Hodgkin's lymphoma that involves the brain, spinal cord, or leptomeninges, without evidence of systemic disease. This rare disease accounts for ~ 3% of all primary central nervous ... Full text Link to item Cite

Ibrutinib in primary central nervous system diffuse large B-cell lymphoma.

Journal Article CNS Oncol · March 1, 2020 The standard regimen for the treatment of newly diagnosed primary CNS lymphoma (PCNSL) remains regimens that contain high-dose methotrexate (MTX). While these regimens can provide control for some patients, there is a dearth of options for the treatment of ... Full text Link to item Cite

Utilizing a Palliative Care Screening Tool in Patients With Glioblastoma.

Journal Article J Adv Pract Oncol · 2020 Patients with glioblastoma have poor overall survival and experience significant burden from neurologic decline and adverse treatment effects. Despite the well-known benefits of early palliative care integration with oncology care, utilization of palliativ ... Full text Open Access Link to item Cite

Geriatric Assessment Identifies Impairments in Younger Candidates for Allogeneic Hematopoietic Stem Cell Transplantation

Conference Blood · November 13, 2019 Introduction: Geriatric assessment (GA) is a multidimensional evaluation of patient health and function that may detect impairments not identified as part of routine care, predict treatment-related morbidity and mortality, and inform treatment plan ... Full text Cite

The role of chemotherapy in the treatment of central neurocytoma.

Journal Article CNS Oncol · November 1, 2019 Aim: Central neurocytoma (CN) is a rare WHO grade II central nervous system (CNS) tumor. This is an update on chemotherapeutic agents used in its treatment. Patients & methods: An institutional review board-approved, chart review of patients seen at our in ... Full text Open Access Link to item Cite

Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview.

Journal Article Support Care Cancer · October 2019 Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating condition associated with a number of chemotherapeutic agents. Drugs commonly implicated in the development of CIPN include platinum agents, taxanes, vinca alkaloids, bortezomib ... Full text Link to item Cite

PL3.1 A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: results from cohort 1

Conference Neuro-Oncology · September 6, 2019 AbstractBACKGROUNDMutant isocitrate dehydrogenase (mIDH) enzymes produce the oncometabolite D-2-hydroxyglutarate (2-HG). Ivosidenib (I ... Full text Cite

Second primary cancers in long-term survivors of glioblastoma.

Journal Article Neurooncol Pract · September 2019 BACKGROUND: Overall survival (OS) in glioblastoma (GBM) is poor at an average of 14 to 18 months, and long-term survivors (LTS) of GBM are rare. LTS of GBM, defined as surviving >5 years postdiagnosis, represent only 2% to 10% of all GBM patients. LTS of c ... Full text Link to item Cite

Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population.

Journal Article Complement Ther Clin Pract · August 2019 BACKGROUND AND PURPOSE: Little is known about complementary and integrative health intervention usage in the primary brain tumor population. We aimed to identify the percentage of patients using these practices and explore the impact on quality of life. MA ... Full text Link to item Cite

Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.

Conference Journal of Clinical Oncology · May 20, 2019 e13526 Background: Recurrence of high-grade glioma (HGG) (WHO grade III-IV) is a nearly universal phenomenon and necessitates the development of new therapeutic modalities. Two possible immunotherapeutic modalities are checkpoint ... Full text Cite

Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.

Conference Journal of Clinical Oncology · May 20, 2019 2060 Background: We completed a study evaluating a single intratumoral delivery of PVSRIPO in recurrent WHO grade IV MG patients (N Engl J Med. 2018 Jul 12;379(2):150-161). Some patients who originally benefitted from the infusion of PVSRIPO demonstrated ... Full text Link to item Cite

A phase I, open label, perioperative study of AG-120 and AG-881 in recurrent IDH1 mutant, low-grade glioma: Results from cohort 1.

Conference Journal of Clinical Oncology · May 20, 2019 2003 Background: AG-120 (ivosidenib [IVO]) is a first-in-class oral inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1) evaluated in 66 glioma patients (pts) in an ongoing phase 1 study. AG-881 (vorasidenib [VOR]) is an oral, ... Full text Cite

Neurooncology Research in Nigeria: Great Untapped Potential.

Journal Article World Neurosurg · April 2019 BACKGROUND: Nigeria has the largest population in Africa and has suboptimal access to neurooncology care. It has been estimated that there is approximately 1 neurosurgeon for every 2.4 million people in the country, with only few of these trained in the ne ... Full text Link to item Cite

Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice.

Journal Article Health Sci Rep · April 2019 BACKGROUND AND AIMS: This retrospective review of patients with recurrent glioblastoma treated at the Preston Robert Tisch Brain Tumor Center investigated treatment patterns, survival, and safety with bevacizumab in a real-world setting. METHODS: Adult pat ... Full text Link to item Cite

Recurrent Extradural Myxopapillary Ependymoma With Oligometastatic Spread.

Journal Article Front Oncol · 2019 Myxopapillary ependymomas are a slow-growing, grade I type glial tumor in the lumbosacral region. More rarely, they can present as extradural, subcutaneous sacrococcygeal, or perisacral masses, and it is under these circumstances that they are more likely ... Full text Link to item Cite

Pilot Study to Describe the Trajectory of Symptoms and Adaptive Strategies of Adults Living with Low-grade Glioma.

Journal Article Semin Oncol Nurs · December 2018 OBJECTIVES: To describe the adaptability to the patterns in symptoms and quality of life (QoL) during 6 months post low-grade glioma diagnosis by valid and reliable tools; to identify through qualitative interviews patient/provider adaptive techniques and ... Full text Link to item Cite

Evidence-based Treatment for Low-grade Glioma.

Journal Article Semin Oncol Nurs · December 2018 OBJECTIVES: To identify the tumors included in the WHO classification of low-grade gliomas, and review the importance of molecular biomarkers and their implication for treatment, prognosis, and outcomes. DATA SOURCES: Published research, clinical guideline ... Full text Link to item Cite

Impact of glioblastoma (GBM)-related cognitive dysfunction (CD) on caregiver burden: Preliminary results from multi-site study in the U.S.

Conference Journal of Clinical Oncology · December 1, 2018 16 Background: GBM is a largely incurable, highly aggressive cancer with high incidence of CD. Caregivers face heightened stress with loved one’s limited life expectancy and additional duties. To better understand this unique gro ... Full text Cite

PSYCHOSOCIAL DISTRESS IN PATIENTS WITH RECURRENT MENINGIOMAS

Conference NEURO-ONCOLOGY · November 5, 2018 QOLP-13 ... Full text Link to item Cite

A Diffuse Leptomeningeal Glioneuronal Tumor Without Diffuse Leptomeningeal Involvement: Detailed Molecular and Clinical Characterization.

Journal Article J Neuropathol Exp Neurol · September 1, 2018 Prior to their provisional WHO classification as a distinct entity in 2016, diffuse leptomeningeal glioneuronal tumors (DLGNT) were often regarded as diffuse leptomeningeal presentations of oligodendrogliomas or extraventricular neurocytomas. Their classif ... Full text Link to item Cite

Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.

Journal Article Oncologist · August 2018 LESSONS LEARNED: Due to evolving imaging criteria in brain tumors and variation in magnetic resonance imaging evaluation, it is not ideal to use response rate as a primary objective. Future studies involving antiangiogenic agents should use overall surviva ... Full text Link to item Cite

Recurrent Glioblastoma Treated with Recombinant Poliovirus.

Journal Article N Engl J Med · July 12, 2018 BACKGROUND: The prognosis of patients with recurrent World Health Organization (WHO) grade IV malignant glioma is dismal, and there is currently no effective therapy. We conducted a dose-finding and toxicity study in this population of patients, evaluating ... Full text Link to item Cite

Long-term outcomes of adult patients with ependymoma.

Conference Neurology · April 27, 2018 150 ... Link to item Cite

Long-term outcomes of adult patients with ependymoma.

Journal Article Neurology · April 10, 2018 150 ... Link to item Cite

Adult pilocytic astrocytoma: clinical management and prognostic factors.

Conference Neurology · April 9, 2018 158 Objective: The purpose of this study is to analyze adult patients with pilocytic astrocytomas and to identify factors associated with recurrence and survival. Background: Pilocytic astrocytomas (WHO grade I) represent the most common central nervous s ... Link to item Cite

Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.

Journal Article J Neurooncol · April 2018 Prognosis of recurrent glioblastoma (GBM) is poor with 6-month progression-free survival (PFS6) ranging from 9 to 48% depending on the treatment regimen and use of anti-angiogenic therapies. We sought to study vorinostat (VOR), a histone deacetylase inhibi ... Full text Link to item Cite

Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.

Journal Issue Oncologist · February 2018 LESSONS LEARNED: Combination regimen with bevacizumab (BEV) and vorinostat is well tolerated in patients with recurrent glioblastoma.Treatment of recurrent glioblastoma remains challenging as this study and others attempt to improve progression-free surviv ... Full text Link to item Cite

Adjunctive perampanel for glioma-associated epilepsy.

Journal Article Epilepsy Behav Case Rep · 2018 Glioma-associated epilepsy is associated with excessive glutamate signaling. We hypothesized that perampanel, an amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptor antagonist, would treat glioma-related epilepsy. We conducted ... Full text Link to item Cite

NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017.

Journal Article J Natl Compr Canc Netw · November 2017 For many years, the diagnosis and classification of gliomas have been based on histology. Although studies including large populations of patients demonstrated the prognostic value of histologic phenotype, variability in outcomes within histologic groups l ... Full text Link to item Cite

PATTERNS OF RELAPSE AFTER SUCCESSFUL COMPLETION OF INITIAL THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Conference Neuro-Oncology · November 1, 2017 RATE-36 INTRODUCTION Primary central nervous system lymphoma (PCNSL) is a subtype of non-Hodgkin’s lymphoma that involves the brain, spinal cord or leptomeninges, without evidence of systemic disease. This rare disease accounts for ~3% of all primary centr ... Full text Link to item Cite

Management of glioblastoma in elderly patients.

Journal Article J Neurol Sci · September 15, 2017 Glioblastoma (GBM) is the most common primary malignant brain tumor in adults over 55years of age. The median age of diagnosis for patients with GBM is 64years old, with the incidence of patients between 75 and 85 increasing. The optimal treatment paradigm ... Full text Link to item Cite

A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population.

Journal Article J Neurooncol · September 2017 Primary brain tumor patients experience high levels of distress. The purpose of this cross-sectional, retrospective study is to evaluate the level and different sources of psychosocial distress and how these pertain to health-related quality of life (HRQoL ... Full text Link to item Cite

Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG).

Conference Journal of Clinical Oncology · May 20, 2017 e13533 Background: The live attenuated oral poliovirus vaccine was modified to contain a heterologous internal ribosomal entry site stemming from human rhinovirus type 2, creating PVSRIPO. PVSRIPO recognizes CD155, an oncofetal c ... Full text Link to item Cite

Phase 1 single-center, dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma.

Conference Journal of Clinical Oncology · May 20, 2017 e13532 Background: D2C7 immunotoxin (D2C7-IT) is a dual-specific recombinant immunotoxin consisting of EGFR-wt and EGFRvIII monoclonal antibodies with a genetically engineered Pseudomonas exotoxin, PE-38KDEL. The primary objectiv ... Full text Link to item Cite

Reductions in exercise behavior and tumor progression in newly diagnosed glioblastoma (GBM) patients.

Conference Journal of Clinical Oncology · May 20, 2017 e21636 Background: At diagnosis, GBM patients face the immediate challenge of significant morbidity and mortality. In this population, we have shown that better exercise behavior is an independent prognostic factor for improved s ... Full text Link to item Cite

Treatment through progression with ofranogene obadenovec (VB-111), an anti-cancer viral therapy, significantly attenuates tumor growth in recurrent GBM: Individual phase 2 patient data.

Conference Journal of Clinical Oncology · May 20, 2017 2055 Background: Ofranergene obadenovec (VB-111) is a viral cancer-therapy with a dual mechanism: vascular disruption and induction of a tumor directed immune response. Prolongation of overall survival (OS) has been shown in recu ... Full text Cite

Radiogenomics of lower-grade glioma: algorithmically-assessed tumor shape is associated with tumor genomic subtypes and patient outcomes in a multi-institutional study with The Cancer Genome Atlas data.

Journal Article J Neurooncol · May 2017 Recent studies identified distinct genomic subtypes of lower-grade gliomas that could potentially be used to guide patient treatment. This study aims to determine whether there is an association between genomics of lower-grade glioma tumors and patient out ... Full text Link to item Cite

Tumor stem cell RNA-leaded dedritic cell vaccine for recurrent glioblastoma: a phase 1 trail.

Conference Neurology · April 27, 2017 Objective: To evaluate the feasibility and safety of administering brain tumor stem cell (BTSC) mRNA-loaded dendritic cells (DC) to patients with recurrent GBM. Background: BTSC CD133+ contribute to GBM propagation and are associated with chemo-radiation ... Link to item Cite

Algorithmic three-dimensional analysis of tumor shape in MRI improves prognosis of survival in glioblastoma: a multi-institutional study.

Journal Article J Neurooncol · March 2017 In this retrospective, IRB-exempt study, we analyzed data from 68 patients diagnosed with glioblastoma (GBM) in two institutions and investigated the relationship between tumor shape, quantified using algorithmic analysis of magnetic resonance images, and ... Full text Link to item Cite

Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients.

Journal Article Crit Rev Oncol Hematol · March 2017 Since 2005, the standard of care for patients with newly diagnosed glioblastoma (GBM) has consisted of maximal resection followed by radiotherapy plus daily temozolomide (TMZ), followed by maintenance TMZ. In patients selected for clinical trials, median o ... Full text Link to item Cite

A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab.

Journal Article Ther Clin Risk Manag · 2017 PURPOSE: Given that the prognosis of recurrent malignant glioma (MG) remains poor, improving quality of life (QoL) through symptom management is important. Meta-analyses establishing antiemetic guidelines have demonstrated the superiority of palonosetron ( ... Full text Link to item Cite

Radiogenomic analysis of lower grade glioma: A pilot multi-institutional study shows an association between quantitative image features and tumor genomics

Conference Progress in Biomedical Optics and Imaging Proceedings of SPIE · January 1, 2017 Recent studies showed that genomic analysis of lower grade gliomas can be very effective for stratification of patients into groups with different prognosis and proposed specific genomic classifications. In this study, we explore the association of one of ... Full text Cite

Antiangiogenic virotherapy: VB-111 targeting glioma

Journal Article Expert Opinion on Orphan Drugs · November 1, 2016 Introduction: High grade gliomas continue to represent a group of cancers that are difficult to control with current cytotoxics and antiangiogenics. With tumor angiogenesis representing a critical mechanism, there is an unmet need for novel types of treatm ... Full text Cite

Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients.

Journal Article CNS Oncol · October 2016 All cancer patients experience distress from the diagnosis, the effects of the disease or the treatment. Clinically significant distress decreases overall quality of life and the recognition of distress with prompt intervention is essential. The National C ... Full text Link to item Cite

Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).

Conference Support Care Cancer · October 2016 BACKGROUND: In malignant glioma (MG) patients undergoing radiation therapy (RT) with concomitant temozolomide, chemoradiation-induced nausea and vomiting (cRINV) degrades quality of life (QoL) and reduces treatment adherence, which thereby potentially comp ... Full text Link to item Cite

Assessment of early response to tumor-treating fields in newly diagnosed glioblastoma using physiologic and metabolic MRI: initial experience.

Journal Article CNS Oncol · July 2016 Tumor-treating fields (TTFields) is a novel antimitotic treatment modality for patients with glioblastoma. To assess response to TTFields, a newly diagnosed patient with glioblastoma underwent diffusion, perfusion and 3D echo-planar spectroscopic imaging p ... Full text Link to item Cite

Neurobehavioral radiation mitigation to standard brain cancer therapy regimens by Mn(III) n-butoxyethylpyridylporphyrin-based redox modifier.

Journal Article Environ Mol Mutagen · June 2016 Combinations of radiotherapy (RT) and chemotherapy have shown efficacy toward brain tumors. However, therapy-induced oxidative stress can damage normal brain tissue, resulting in both progressive neurocognitive loss and diminished quality of life. We have ... Full text Link to item Cite

Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.

Conference Journal of Clinical Oncology · May 20, 2016 Background: The live attenuated oral (SABIN) serotype 1 poliovirus vaccine was modified to contain a heterologous internal ribosomal entry site stemming from human rhinovirus type 2, creating PVSRIPO. PVSRIPO recognizes CD155, an oncofetal cell adhesion mo ... Full text Link to item Cite

Phase I trial of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM).

Conference Journal of Clinical Oncology · May 20, 2016 ackground: The inherent biologic specificity of immunotherapy offers the prospect of targeting neoplastic cells more precisely. Dendritic cells (DCs) are endowed with an extraordinary ability to activate CD4+ and CD8+ T-cells, and DCs loaded with antigens ... Full text Link to item Cite

Baseline cognitive function to predict survival in patients with glioblastoma.

Conference Journal of Clinical Oncology · May 20, 2016 Background: Overall survival of patients with glioblastoma (GBM) remains dismal with range from 12-14 months. In addition to the oncologic burden that these patients face during the disease trajectory, there are demonstrable neurologic and cognitive challe ... Full text Link to item Cite

Insomnia and its associations in patients with recurrent glial neoplasms.

Journal Article Springerplus · 2016 BACKGROUND: Patient with neurological disorders and cancer can develop sleep disturbance, in particular insomnia. Etiology of insomnia is multi-factorial in primary brain tumour patients with possible causes including corticosteroids, psychoactive medicati ... Full text Open Access Link to item Cite

Postictal Magnetic Resonance Imaging Changes Masquerading as Brain Tumor Progression: A Case Series.

Journal Article Case Rep Oncol · 2016 Seizures are common among patients with brain tumors. Transient, postictal magnetic resonance imaging abnormalities are a long recognized phenomenon. However, these radiographic changes are not as well studied in the brain tumor population. Moreover, rever ... Full text Link to item Cite

Radiogenomics of glioblastoma: A pilot multi-institutional study to investigate a relationship between tumor shape features and tumor molecular subtype

Conference Progress in Biomedical Optics and Imaging Proceedings of SPIE · January 1, 2016 Genomic subtype has been shown to be an important predictor of therapy response for patients with glioblastomas. Unfortunately, obtaining the genomic subtype is an expensive process that is not typically included in the standard of care. It is therefore of ... Full text Cite

Predicting outcomes in glioblastoma patients using computerized analysis of tumor shape - Preliminary data

Conference Progress in Biomedical Optics and Imaging Proceedings of SPIE · January 1, 2016 Glioblastoma (GBM) is the most common primary brain tumor characterized by very poor survival. However, while some patients survive only a few months, some might live for multiple years. Accurate prognosis of survival and stratification of patients allows ... Full text Cite

Single-Agent Carboplatin for a Rare Case of Pilomyxoid Astrocytoma of the Spinal Cord in an Adult with Neurofibromatosis Type 1.

Journal Article Case Rep Oncol · 2016 INTRODUCTION: Pilomyxoid astrocytoma (PMA) is a rare and more aggressive variant of pilocytic astrocytoma, which usually affects young children and is most often located in the hypothalamic/chiasmatic region. The association of PMA with underlying genetic ... Full text Link to item Cite

Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.

Journal Article Oncologist · July 2015 LESSONS LEARNED: Trials focusing on unresectable multifocal glioblastoma are needed because of the extremely poor prognosis and challenges in receiving standard therapy, such as concurrent radiation and chemotherapy.Developing a strategy to chemically debu ... Full text Link to item Cite

Secondary cancers in long-term survivors of primary glioblastoma.

Conference JOURNAL OF CLINICAL ONCOLOGY · May 20, 2015 Link to item Cite

Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.

Conference Journal of Clinical Oncology · May 20, 2015 Full text Cite

Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.

Conference Journal of Clinical Oncology · May 20, 2015 2034 ... Link to item Cite

Radioprotection of the brain white matter by Mn(III) n-Butoxyethylpyridylporphyrin-based superoxide dismutase mimic MnTnBuOE-2-PyP5+.

Journal Article Mol Cancer Ther · January 2015 Cranial irradiation is a standard therapy for primary and metastatic brain tumors. A major drawback of radiotherapy (RT), however, is long-term cognitive loss that affects quality of life. Radiation-induced oxidative stress in normal brain tissue is though ... Full text Link to item Cite

Supratentorial tanycytic ependymoma in an adult male: case report and review of literature.

Journal Article Case Rep Oncol · 2015 Ependymomas, tumors of the ependymal cells, are very rare and usually present in the pediatric population. Furthermore, there are even rarer variants of ependymomas that can include cellular, papillary, clear cell, and tanycytic subtypes. We present a case ... Full text Open Access Link to item Cite

Use of bevacizumab in recurrent glioblastoma.

Journal Article CNS Oncol · 2015 Glioblastoma (GBM) is the most common adult primary brain neoplasm. Despite advances in treatment, GBM continues to be associated with considerable morbidity and mortality as compared with other malignancies. Standard treatment for GBM results in survival ... Full text Link to item Cite

Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients.

Journal Article J Neurooncol · December 2014 Quality of life (QoL) impairment and fatigue are frequently experienced during treatment for recurrent high-grade glioma (HGG). Fatigue and QoL impairments can be due to primary neurological dysfunction, cytotoxic treatments, mood disturbances, and support ... Full text Link to item Cite

Computer-extracted MR imaging features are associated with survival in glioblastoma patients.

Journal Article J Neurooncol · December 2014 Automatic survival prognosis in glioblastoma (GBM) could result in improved treatment planning for the patient. The purpose of this research is to investigate the association of survival in GBM patients with tumor features in pre-operative magnetic resonan ... Full text Link to item Cite

Oncolytic polio/rhinovirus recombinant (pvsripo) in recurrent glioblastoma (gbm): first phase I clinical trial evaluating the intratumoral administration.

Journal Article Neuro Oncol · July 2014 PVSRIPO is the live attenuated, oral (SABIN) serotype 1 poliovirus vaccine containing a heterologous internal ribosomal entry site stemming from human rhinovirus type 2. PVSRIPO recognizes nectin-like molecule-5, an oncofetal cell adhesion molecule and tum ... Full text Link to item Cite

Relationship between exercise behavior, cardiorespiratory fitness, and cognitive function in early breast cancer patients treated with doxorubicin-containing chemotherapy: a pilot study.

Journal Article Appl Physiol Nutr Metab · June 2014 The purpose of this study was to examine the relationship between self-reported exercise behavior, cardiorespiratory fitness (CRF), and cognitive function in early breast cancer patients. Thirty-seven breast cancer patients following completion of chemothe ... Full text Link to item Cite

Tumor progression and transformation of low-grade glial tumors associated with pregnancy.

Journal Article J Neurooncol · January 2014 Brain tumor growth or progression has been shown to occur in low-grade glial tumors and meningiomas. While progression has been documented in this population, transformation to a more aggressive high-grade glial tumor that can lead to increased morbidity a ... Full text Link to item Cite

Acquired stuttering due to recurrent anaplastic astrocytoma.

Journal Article BMJ case reports · December 1, 2013 Acquired (neurogenic) stuttering is a rare phenomenon seen after cerebral infarction or brain injury. Aetiology of this symptom is unclear, but recent evidence supports that it is a disturbance in the left hemispheric neural network involving the interplay ... Cite

Acquired stuttering due to recurrent anaplastic astrocytoma.

Journal Article BMJ Case Rep · November 19, 2013 Acquired (neurogenic) stuttering is a rare phenomenon seen after cerebral infarction or brain injury. Aetiology of this symptom is unclear, but recent evidence supports that it is a disturbance in the left hemispheric neural network involving the interplay ... Full text Link to item Cite

Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial.

Journal Article Int J Radiat Oncol Biol Phys · August 1, 2013 PURPOSE: Virtually all patients with malignant glioma (MG) eventually recur. This study evaluates the safety of concurrent stereotactic radiosurgery (SRS) and bevacizumab (BVZ), an antiangiogenic agent, in treatment of recurrent MG. METHODS AND MATERIALS: ... Full text Link to item Cite

107 Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.

Journal Article Neurosurgery · August 2013 Current therapies for glioblastoma are limited by ineffective delivery beyond the blood-brain barrier, limited diffusion of regionally-delivered macromolecules, and lack of tumor specificity. Sustained direct intracerebral infusion at slow flow rates [conv ... Full text Link to item Cite

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.

Journal Article Cancer Med · April 2013 Patients with unresectable glioblastomas have a poor prognosis, with median survival of 6-10 months. We conducted a phase II trial of upfront 5-day temozolomide (TMZ) and bevacizumab (BV) in patients with newly diagnosed unresectable or multifocal glioblas ... Full text Open Access Link to item Cite

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.

Journal Article Br J Cancer · October 23, 2012 BACKGROUND: Bevacizumab improves outcome for most recurrent glioblastoma patients, but the duration of benefit is limited and survival after initial bevacizumab progression is poor. We evaluated bevacizumab continuation beyond initial progression among rec ... Full text Open Access Link to item Cite

Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.

Journal Article Cancer · October 1, 2012 BACKGROUND: We evaluated the efficacy of imatinib plus hydroxyurea in patients with progressive/recurrent low-grade glioma. METHODS: A total of 64 patients with recurrent/progressive low-grade glioma were enrolled in this single-center study that stratifie ... Full text Link to item Cite

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.

Journal Article J Neurooncol · August 2012 Intracranial meningiomas are often indolent tumors which typically grow over years to decades. Nonetheless, meningiomas that progress after maximum safe resection and radiation therapy pose a significant therapeutic challenge and effective therapies have y ... Full text Link to item Cite

Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.

Journal Article J Neurooncol · July 2012 To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of dasatinib, an inhibitor of the Src family kinase proteins, with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, among recurrent malignant glioma pat ... Full text Link to item Cite

Disseminated Intracranial Ewing's Sarcoma in an Adult: A Rare and Difficult Diagnosis.

Journal Article Case Rep Oncol · May 2012 The Ewing sarcoma family of tumors comprises a rare class of cancers of mesenchymal origin. Cases of Ewing's sarcoma in the central nervous system - specifically, intracranial Ewing's - are extremely rare. Almost all reported cases have occurred in childre ... Full text Link to item Cite

Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.

Journal Article Int J Radiat Oncol Biol Phys · April 1, 2012 PURPOSE: Patients with recurrent malignant gliomas treated with stereotactic radiosurgery (SRS) and multiagent systemic therapies were reviewed to determine the effects of patient- and treatment-related factors on survival and toxicity. METHODS AND MATERIA ... Full text Link to item Cite

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.

Journal Article J Neurooncol · March 2012 We evaluated the efficacy of carboplatin, irinotecan, and bevacizumab among bevacizumab-naïve, recurrent glioblastoma (GBM) patients in a phase 2, open-label, single arm trial. Forty eligible patients received carboplatin (area under the plasma curve [AUC] ... Full text Link to item Cite

Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.

Journal Article J Neurooncol · March 2012 Although outcome following bevacizumab among recurrent grade IV malignant glioma patients is documented as poor by several analyses, outcome for recurrent grade III patients following bevacizumab therapy has not been specifically evaluated. We performed a ... Full text Link to item Cite

Bevacizumab and daily temozolomide for recurrent glioblastoma.

Journal Article Cancer · March 1, 2012 BACKGROUND: The authors performed a phase 2 trial of combined protracted daily temozolomide and biweekly bevacizumab for patients with recurrent glioblastoma who had previously received radiation therapy and temozolomide. METHODS: There was no limit on the ... Full text Link to item Cite

Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.

Journal Article Int J Radiat Oncol Biol Phys · January 1, 2012 PURPOSE: To determine the safety of the addition of bevacizumab to standard radiation therapy and daily temozolomide for newly diagnosed glioblastoma multiforme (GBM). METHODS AND MATERIALS: A total of 125 patients with newly diagnosed GBM were enrolled in ... Full text Link to item Cite

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.

Journal Article J Neurooncol · January 2012 We prospectively evaluated the efficacy and safety of imatinib plus hydroxyurea in patients with progressive/recurrent meningioma. A total of 21 patients with progressive/recurrent meningioma were enrolled in this dual center, single-arm, phase II trial. A ... Full text Link to item Cite

Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.

Journal Article J Neurooncol · December 2011 We determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of the oral vascular endothelial growth factor receptor (VEGFR) inhibitor, sunitinib, when administered with irinotecan among recurrent malignant glioma (MG) patients. For ea ... Full text Link to item Cite

Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.

Journal Article Cancer · December 1, 2011 BACKGROUND: The efficacy of carboplatin, irinotecan, and bevacizumab among recurrent glioblastoma (GBM) patients after prior progression on bevacizumab therapy in a phase 2, open-label, single-arm trial was evaluated. METHODS: Eligible patients received ca ... Full text Link to item Cite

A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.

Journal Article J Neurooncol · December 2011 We conducted a phase I clinical trial of the combination of SCH 66336 with temozolomide administered on the standard 5-day dosing schedule. The primary objective was to determine the maximum tolerated dose and dose limiting toxicity (DLT) of twice daily SC ... Full text Link to item Cite

Everolimus tablets for patients with subependymal giant cell astrocytoma.

Journal Article Expert Opin Pharmacother · October 2011 INTRODUCTION: Better understanding of aberrantly active molecular pathways in tumors offers potential to develop more specific and less toxic therapies. Abnormal mammalian target of rapamycin (mTOR) complex signaling and defects in TSC1 and TSC2 have been ... Full text Link to item Cite

Bevacizumab and Radiosurgery for Recurrent Malignant Glioma: Toxicity Results from a Prospective Pilot Study

Journal Article International Journal of Radiation Oncology*Biology*Physics · October 2011 Full text Cite

Dural venous sinus thrombosis in anaplastic astrocytoma following concurrent temozolomide and focal brain radiotherapy plus bevacizumab.

Journal Article J Neurooncol · September 2011 Malignant gliomas have long been a therapeutic dilemma in neuro-oncology, with a poor overall prognosis. Standard treatment, consisting of primary resection, followed by radiation therapy and temozolomide, has improved prognosis. Recently, studies have loo ... Full text Link to item Cite

Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma.

Journal Article J Clin Oncol · July 20, 2011 PURPOSE: Identifying strong markers of prognosis are critical to optimize treatment and survival outcomes in patients with malignant recurrent glioma. We investigated the prognostic significance of exercise behavior and functional capacity in this populati ... Full text Link to item Cite

Transformation of juvenile pilocytic astrocytoma to anaplastic pilocytic astrocytoma in patients with neurofibromatosis type I.

Journal Article J Pediatr Hematol Oncol · July 2011 Patients with juvenile pilocytic astrocytoma (JPA) and neurofibromatosis type I (NF-1) tend to have a more indolent course than those with sporadic tumors. In rare circumstances, transformation to anaplastic pilocytic astrocytoma (APA) has been known to oc ... Full text Link to item Cite

The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.

Journal Article Clin Cancer Res · June 15, 2011 PURPOSE: To determine if the addition of bevacizumab to radiation therapy and temozolomide, followed by bevacizumab, temozolomide, and irinotecan, for newly diagnosed glioblastoma patients is safe and effective. EXPERIMENTAL DESIGN: A total of 75 patients ... Full text Link to item Cite

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.

Journal Article J Neurooncol · June 2011 We evaluated the efficacy of metronomic etoposide or temozolomide administered with bevacizumab among recurrent glioblastoma (GBM) patients who progressed on prior bevacizumab therapy in a phase 2, open-label, two-arm trial. Twenty-three patients received ... Full text Link to item Cite

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.

Journal Article J Natl Compr Canc Netw · April 2011 Glioblastoma, the most common primary malignant brain tumor among adults, is a highly angiogenic and deadly tumor. Angiogenesis in glioblastoma, driven by hypoxia-dependent and independent mechanisms, is primarily mediated by vascular endothelial growth fa ... Full text Link to item Cite

A comparison of performance-based measures of function in HIV-associated neurocognitive disorders.

Journal Article J Neurovirol · April 2011 The objectives of this study are to compare the results of newer performance-based functional assessments in the study of HIV-associated neurocognitive disorders (HAND) and to correlate these functional assessments with specific levels of severity of HAND. ... Full text Link to item Cite

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.

Journal Article J Neurooncol · January 2011 Sorafenib, an oral VEGFR-2, Raf, PDGFR, c-KIT and Flt-3 inhibitor, is active against renal cell and hepatocellular carcinomas, and has recently demonstrated promising activity for lung and breast cancers. In addition, various protracted temozolomide dosing ... Full text Link to item Cite

Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy.

Journal Article J Neurooncol · January 2011 Striae distensae (stretch marks) are a common complication seen in patients on chronic corticosteroid therapy. Under certain circumstances, primary brain tumor patients require chronic corticosteroid therapy and can suffer from striae distensae. Bevacizuma ... Full text Link to item Cite

Treatment of Recurrent Intracranial Hemangiopericytoma with SRC-Related Tyrosine Kinase Targeted Therapy: A Case Report.

Journal Article Case Rep Oncol · April 8, 2010 Hemangiopericytoma (HPC) is a rare sarcomatous tumor arising from pericytes, a support cell found in blood vessels. These tumors can occur throughout the body, particularly in the lower extremities and retroperitoneum. In rare circumstances, HPCs can arise ... Full text Link to item Cite

Changes in functional performance measures in adults undergoing chemoradiation for primary malignant glioma: a feasibility study.

Journal Article Oncologist · 2010 PURPOSE: To investigate the feasibility of longitudinal assessment of functional performance measures in newly diagnosed postsurgical malignant glioma patients. METHODS: Patients with histologically confirmed, clinically stable, postsurgical, and previousl ... Full text Link to item Cite

Phase I study of vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma.

Journal Article J Clin Oncol · May 20, 2009 e13007 Background: Malignant glioma (MG), an incurable primary CNS tumor, is characterized by frequent aberrant activation of EGFR, VEGFR, and PDGFR. This study will determine the MTD and DLT of vandetanib (V), a once-daily, oral selective inhibitor of VEG ... Link to item Cite

Bevacizumab plus etoposide among recurrent malignant glioma patients: Phase II study final results.

Journal Article J Clin Oncol · May 20, 2009 2046 Background: Significant therapeutic benefit has been observed among recurrent malignant glioma (MG) patients treated with bevacizumab (BV), a neutralizing monoclonal antibody to vascular endothelial growth factor (VEGF) with or without chemotherapy. I ... Link to item Cite

A phase I study of sunitinib plus irinotecan in the treatment of patients with recurrent malignant glioma.

Journal Article J Clin Oncol · May 20, 2009 e13024 Background: Malignant glioma (MG), an incurable primary CNS tumor, are highly angiogenic due to overexpression of VEGF/VEGFR. The current study was designed to determine the MTD and DLT of sunitinib (S), a once-daily, oral selective inhibitor of VEG ... Link to item Cite

Neurologic complications of head and neck cancer

Journal Article · December 1, 2008 Cancers of the oral cavity, nasal cavity, salivary glands, pharynx, and larynx comprise head and neck cancers. These cancers are present not only in the United States but also around the world. Risk factors such as smoking, alcohol, and human papillomaviru ... Full text Cite

Tirapazamine: a hypoxia-activated topoisomerase II poison.

Journal Article Cancer Res · September 15, 2002 Tirapazamine (TPZ), a hypoxia-selective cytotoxin, has demonstrated activity in cancer clinical trials. Under hypoxic conditions, TPZ is reduced to a radical that leads to DNA double-strand breaks (DSBs), single-strand breaks, and base damage. A previous f ... Link to item Cite

Inhibition of DNA replication by tirapazamine.

Journal Article Cancer Res · July 15, 2001 Tirapazamine (TPZ) is a hypoxia-selective cytotoxin that is currently being examined in Phase II and III clinical trials in combination with radiotherapy and cisplatin-based chemotherapy. Reductases convert TPZ to a cytotoxic radical that produces DNA dama ... Link to item Cite

A high-performance liquid chromatographic method to measure sphingosine 1-phosphate and related compounds from sphingosine kinase assays and other biological samples.

Journal Article Anal Biochem · May 15, 2000 Sphingosine 1-phosphate is an intermediate of sphingosine catabolism as well as a potent signaling compound. Conditions were established for the extraction and analysis of sphingosine 1-phosphate and other sphingoid base 1-phosphates from in vitro sphingos ... Full text Link to item Cite